Home/Pipeline/Spine Fusion Program

Spine Fusion Program

Spinal Fusion Surgery

Preclinical/Phase 1Active

Key Facts

Indication

Spinal Fusion Surgery

Phase

Preclinical/Phase 1

Status

Active

Company

Novadip Biosciences

About Novadip Biosciences

Novadip Biosciences is a private, clinical-stage biotech developing a new class of regenerative tissue products derived from adipose (fat) stem cells. The company's core technology platform aims to generate 3D tissues that mimic the natural healing environment, targeting critical challenges in orthopedics and reconstructive surgery. With a pipeline led by programs for congenital pseudarthrosis of the tibia (CPT) and spine fusion, Novadip is positioning itself in the high-growth cell and gene therapy sector. The company operates from Mont-Saint-Guibert, Belgium, and is likely pre-revenue, relying on partnerships and investment to advance its clinical programs.

View full company profile

Therapeutic Areas

Orthopedics Rare Diseases Reconstructive Surgery

Other Spinal Fusion Surgery Drugs

Drug	Company	Phase	Status
U.S. Commercial Expansion (ALTOS®/FORTOS-C™)	Silony Spine	Commercial	Active
Product Portfolio Enhancements & Line Extensions	Silony Spine	Development/Commercial	Active